TwinBeech Capital’s Apellis Pharmaceuticals APLS Stock Holding History

TwinBeech Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,152	Closed	-$330K	–	562
2025 Q4	$330K	Buy	13,152 +4,225	+47%	+$99.1K	0.02%	465
2025 Q3	$202K	Buy	+8,927	New	+$208K	0.01%	526
2024 Q4	–	Sell	-272,252	Closed	-$7.85M	–	607
2024 Q3	$7.85M	Buy	272,252 +214,180	+369%	+$7.93M	0.15%	170
2024 Q2	$2.23M	Buy	+58,072	New	+$2.63M	0.04%	320
2024 Q1	–	Sell	-14,772	Closed	-$884K	–	540
2023 Q4	$884K	Sell	14,772 -135,457	-90%	-$6.87M	0.01%	501
2023 Q3	$5.71M	Buy	+150,229	New	+$6.6M	0.11%	240
2022 Q2	–	Sell	-19,123	Closed	-$972K	–	497
2022 Q1	$972K	Buy	+19,123	New	+$844K	0.04%	324

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TwinBeech Capital's APLS Position: Q1 2026 in Review

TwinBeech Capital sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 13,152 shares — an estimated $330K sold.

TwinBeech Capital first reported a position in APLS in Q1 2022 and held it in 7 quarters. The position peaked at $7.85M in Q3 2024. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

TwinBeech Capital reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
TwinBeech Capital sold 13,152 Apellis Pharmaceuticals shares in Q1 2026, an estimated $330K.
TwinBeech Capital first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 7 quarters.
TwinBeech Capital's Apellis Pharmaceuticals position peaked at $7.85M in Q3 2024.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on TwinBeech Capital's 13F filing for Q1 2026, filed 15 May 2026.